Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-MDD-2: Brenipatide adjunctive therapy in adults with major depressive disorder
CTR20263178Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of brenipatide in major depressive disorder (MDD), sponsored by Eli Lilly and Company. Started Aug 2026; status: active.
02
Drugs
brenipatide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20263178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263178.